💸 The Tape

On Friday, Cultivated reported that Organigram Global has spent the past few weeks in merger talks with Aurora Cannabis, the same Aurora that Curaleaf is chasing with a hostile bid it just raised to US$5 per share. Neither company has confirmed it. Curaleaf’s response was one word long in spirit: outraged.

On the numbers, Curaleaf has a point. Its bid values Aurora at roughly US$325 million. Curaleaf pegs Organigram’s market value near US$200 million. A company does not comfortably buy something 60% larger than itself using stock that trades under a dollar. The math did not work last week, and it has not improved over the weekend.

So here is a different question, and it is purely a thought experiment. Nobody has proposed it, nobody has reported it, and nothing below is a prediction. What if the Organigram report matters less as a deal than as a clue to how a much larger buyer would think?

The thesis

Assume rescheduling is finished in its entirety: a final rule moving all marijuana to Schedule III, with the litigation resolved. Assume that brings big alcohol or tobacco off the sidelines.

A global consumer company does not want a regional licence. It wants a footprint, and the footprint has four boxes: Canadian adult-use, Canadian medical, U.S. medical and adult-use, and the European Union. No single cannabis company fills all four. These three, together, do.

The map

• Organigram is Canada’s No. 1 cannabis company by market share, with recreational sales making up about C$62 million of last quarter’s C$106 million in net revenue. Its acquisition of Sanity Group added a German medical platform.

• Aurora has rebuilt itself as a global medical company. It sells medical cannabis in Canada and in Germany, Poland, Australia and New Zealand, earns 64% of revenue outside Canada, and owns EU-GMP manufacturing, including a just-completed expansion at Leuna in Germany. It carries about C$149 million in cash and no debt. It is also exiting Canadian consumer cannabis, which is precisely the box Organigram fills.

• Curaleaf is the U.S. piece: US$1.27 billion of revenue last year across medical and adult-use markets, plus an international arm with positions in Germany, the U.K. and Poland.

Stack them and you get Canada’s adult-use leader, a medical exporter with pharmaceutical-grade manufacturing, a company that calls itself the world’s largest cannabis operator, and three German platforms. Combined run-rate revenue is roughly US$1.8 billion.

The price tag

At current marks, Curaleaf is worth about US$2.6 billion, Aurora about US$325 million at the bid, and Organigram about US$200 million. That is just over US$3 billion of equity. Add control premiums and Curaleaf’s debt, and the all-in cost lands somewhere around US$5 billion.

For context, Constellation Brands committed about C$5 billion to Canopy Growth in 2018 for a stake in a single Canadian producer. A cheque of the same order, eight years later, would buy leading positions across North America and Europe. Cannabis has been many things since 2018. Expensive is no longer one of them.

The detail hiding in plain sight

Big tobacco is already in the room. BAT holds an economic interest of roughly 48% in Organigram through common and preferred shares, with its voting stake capped at 30%. It put up C$65 million to help fund the Sanity deal.

That changes how the Friday report reads. An Aurora and Organigram merger, whatever its standalone arithmetic, would put a tobacco major’s capital behind the Canada-plus-Europe half of the map. A Curaleaf and Aurora combination would build the U.S.-plus-Europe half. Either pairing leaves the third company as the obvious missing piece.

That is the sense in which the report “makes sense.” It does not work as a bid Organigram can afford. It works as an opening move on a board where a strategic eventually wants all three squares.

Why this stays theoretical

• Rescheduling is not finished. The DEA hearing record is currently stayed, and the D.C. Circuit challenge to the April order will not be fully briefed until February 19, 2027.

• Schedule III is not legalization. Adult-use sales would remain federally unlawful. A strategic listed in London or New York would still need its exchange, lenders and lawyers to get comfortable. The thesis assumes they do, and that is a large assumption.

• Control is not for sale by default. Curaleaf chairman Boris Jordan holds multiple voting shares, and BAT’s voting cap at Organigram exists for a reason.

• History is unkind. Constellation wrote down its Canopy investment heavily. Strategics have long memories and longer board meetings.

The takeaway

The Aurora fight is being argued as a question of whose stock is the better currency. Through a strategic buyer’s lens, the question is which combination assembles the map fastest.

This is speculation, and it should be treated as such. But it does explain why a US$200 million company turning up at a US$325 million auction is less absurd than the arithmetic suggests. Arithmetic says no. Strategy says maybe later.

📈 Dog Walkers

$CGC ( ▼ 8.42% ) Flaunts EU GMP Capes

Canopy Growth has secured EU-GMP certification for manufacturing and packaging at its Smiths Falls, Ontario facility, giving the company a credential it says no other Canadian cannabis site can match.

The certification was issued by the Tübingen Regional Council, the medicines regulator for the German state of Baden-Württemberg. It covers softgel manufacturing plus primary packaging of softgels, oral liquids and dried flower. Canopy says Smiths Falls is now the only Canadian cannabis facility certified for that combined scope, based on its review of European regulatory records as of October 9.

The practical point is control. Canopy can now make and package patient-ready medical products for Europe inside its own walls, rather than handing the final steps to someone else and sharing the margin. CEO Luc Mongeau framed it as capturing more value across the supply chain, which is executive for “we would like to keep the money.”

The near-term targets are Germany, Poland and the U.K. The news follows a renewed EU-GMP certification at the company’s Kincardine site, an expansion of Spectrum Therapeutics flower into the U.K., and the appointment of a German country manager effective October 1.

What the release does not include is numbers. There is no capacity figure, revenue target or first-shipment date, so the certification is a capability for now, not yet a contribution.

Still, the timing is notable. With Curaleaf, Aurora and Organigram all jostling over European medical assets, Canopy is making clear it intends to compete there on finished products, not just bulk flower.

$TLRY ( ▼ 5.09% ) Brings Testing In-House

Tilray Medical has won approval to run its own quality control testing at its EU-GMP-certified facility in Cantanhede, Portugal, removing a step that previously sat with outside labs.

The approval comes from INFARMED, Portugal’s medicines regulator, and covers microbiological and chemical/physical testing in the site’s quality control laboratory. Until now, Tilray relied on third-party labs to test flower lots before release.

The pitch is simple: fewer handoffs. Tilray says in-house testing should mean lower batch-release costs, shorter testing timelines and faster movement from harvest to sale. The product is headed for Germany, the U.K., Poland and Italy, along with other regulated medical markets.

Rajnish Ohri, Tilray’s president of international, said the approval gives the company more speed, control and flexibility across its international supply chain. He added that the leaders in maturing medical markets will be those combining pharmaceutical-grade quality with reliable supply. The release describes Cantanhede as a “launchpad” for that effort, building on increased output at the site and expanded distribution in the U.K.

As with most announcements of this kind, the specifics are light. There are no figures for days saved, dollars saved or volumes affected, so investors will have to wait for the margin line to tell the story.

The context makes it more interesting. Tilray just reported record quarterly revenue of $257.1 million, but that was powered by beverages, while cannabis revenue fell 13%. International medical is the part of the cannabis business with room to grow, and release speed is a real constraint when every batch needs paperwork before it ships.

It also landed on the same morning Canopy Growth announced EU-GMP certification for softgel manufacturing and packaging in Ontario. Two Canadian producers, two European supply-chain upgrades, one news cycle. The race for Europe is increasingly being run in the lab and on the packaging line, which is less glamorous than a takeover fight but considerably cheaper.

📺 Trade To Black

Two Tracks Decide Cannabis Rescheduling | TDR Cannabis in 5

• Rescheduling is running on two tracks. The DEA hearing is paused after opponents asked to add a federal report on gaps in the scheduling process, and the consolidated D.C. Circuit case now has an agreed briefing schedule.

• Opening briefs are due November 24, the government responds January 13, and final briefs land February 19, 2027, with oral argument targeted before the court’s summer recess.

• The opponents’ scorecard so far: the D.C. Circuit refused to pause rescheduling, Louisiana’s attorney general pulled out of the state suit, and a related Medicare hemp case was dismissed.

• The process was built to absorb legal hits, but the risk remains: the hearing decides whether full rescheduling happens, the lawsuits decide whether it holds, and a 2027 ruling against the government could still undo the medical order.